1. Combined analysis of gene expression, miRNA expression and DNA methylation profiles of osteosarcoma
    Wenpeng Zhang et al, 2017 CrossRef
  2. Resveratrol in management of bone and spinal cancers
    Gang Chen et al, 2017, Natural Product Research CrossRef
  3. Isoliquiritigenin inhibits colorectal cancer cells HCT-116 growth by suppressing the PI3K/AKT pathway
    Ya-Li Huang et al, 2017 CrossRef
  4. Downregulation of BZW2 inhibits osteosarcoma cell growth by inactivating the Akt/mTOR signaling pathway
    Dong-Dong Cheng et al, 2017 CrossRef
  5. EEF1D overexpression promotes osteosarcoma cell proliferation by facilitating Akt-mTOR and Akt-bad signaling
    Dong-dong Cheng et al, 2018, J Exp Clin Cancer Res CrossRef
  6. Exploring the key genes and pathways of side population cells in human osteosarcoma using gene expression array analysis
    Yi-Ming Ren et al, 2018, J Orthop Surg Res CrossRef
  7. Clinical case report of patients with osteosarcoma and anticancer benefit of calycosin against human osteosarcoma cells
    Rubiao Qiu et al, 2019, J Cell Biochem CrossRef
  8. Long Noncoding RNA SNHG16 Promotes Osteosarcoma Cells Migration and Invasion via Sponging miRNA-340.
    Pan Su et al, 2019, DNA Cell Biol CrossRef
  9. mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy.
    Tian Tian et al, 2019, Int J Mol Sci CrossRef
  10. Nitidine Chloride Inhibits SIN1 Expression in Osteosarcoma Cells
    Hui Xu et al, 2019, Molecular Therapy - Oncolytics CrossRef
  11. Role of autophagy in osteosarcoma.
    Olivier Camuzard et al, 2019, J Bone Oncol CrossRef
  12. Germline and somatic genetics of osteosarcoma - connecting aetiology, biology and therapy.
    D Matthew Gianferante et al, 2017, Nat Rev Endocrinol CrossRef
  13. miR-342-5p inhibits osteosarcoma cell growth, migration, invasion, and sensitivity to Doxorubicin through targeting Wnt7b
    Qing Liu et al, 2019, Cell Cycle CrossRef
  14. Targeting glucose metabolism to suppress cancer progression: prospective of anti-glycolytic cancer therapy
    Ali F. Abdel-Wahab et al, 2019, Pharmacological Research CrossRef
  15. Omic approaches to pediatric bone sarcomas
    Elisa Tirtei et al, 2019, Pediatr Blood Cancer CrossRef
  16. mTOR Links Tumor Immunity and Bone Metabolism: What are the Clinical Implications?
    Azzurra Irelli et al, 2019, IJMS CrossRef
  17. Natural products targeting the PI3K-Akt-mTOR signaling pathway in cancer: A novel therapeutic strategy
    Devesh Tewari et al, 2019, Seminars in Cancer Biology CrossRef
  18. Estrogen receptor β induces autophagy of osteosarcoma through the mTOR signaling pathway
    Zhengming Yang et al, 2020, J Orthop Surg Res CrossRef
  19. COX-2 promotes metastasis and predicts prognosis on gastric cancer via regulating mTOR
    Liangliang Xiang et al, 2020, Biomarkers in Medicine CrossRef
  20. PLK1 Knockdown Inhibits Cell Proliferation and Cell Apoptosis, and PLK1 Is Negatively Regulated by miR-4779 in Osteosarcoma Cells
    Jiajun Zhu et al, 2020, DNA and Cell Biology CrossRef
  21. Identification of the miRNA-mRNA regulatory network of small cell osteosarcoma based on RNA-seq
    Lin Xie et al, 2017, Oncotarget CrossRef
  22. Tetrahydrocurcumin induces mesenchymal-epithelial transition and suppresses angiogenesis by targeting HIF-1α and autophagy in human osteosarcoma
    Yan Zhang et al, 2017, Oncotarget CrossRef
  23. Co-expression network analysis identifies a gene signature as a predictive biomarker for energy metabolism in osteosarcoma
    Naiqiang Zhu et al, 2020, Cancer Cell Int CrossRef
  24. Suppression of CLEC3A inhibits osteosarcoma cell proliferation and promotes their chemosensitivity through the AKT1/mTOR/HIF1α signaling pathway
    Chong Ren et al, 2020, Mol Med Report CrossRef
  25. TRIM2 regulates the development and metastasis of tumorous cells of osteosarcoma.
    Yi Qin et al, 2018, Int J Oncol CrossRef
  26. miR-27a-3p promotes the malignant phenotypes of osteosarcoma by targeting ten-eleven translocation 1
    Jin Liu et al, 2018, Int J Oncol CrossRef
  27. Honokiol induces autophagy and apoptosis of osteosarcoma through PI3K/Akt/mTOR signaling pathway
    Zhiquan Li et al, 2017, Mol Med Report CrossRef
  28. Expression of miR‑542‑3p in osteosarcoma with miRNA microarray data, and its potential signaling pathways
    Zhen Li et al, 2018, Mol Med Report CrossRef
  29. Bone morphogenetic protein and activin membrane‑bound inhibitor suppress bone cancer progression in MG63 and SAOS cells via regulation of the TGF‑β‑induced EMT signaling pathway
    Fengsong Liu et al, 2018, Oncol Lett CrossRef
  30. Cellular plasticity and drug resistance in sarcoma
    Zhengjun Lin et al, 2020, Life Sciences CrossRef
  31. Ezrin Mediates Invasion and Metastasis in Tumorigenesis: A Review
    Yanan Song et al, 2020, Front. Cell Dev. Biol. CrossRef
  32. Arbutin suppresses osteosarcoma progression via miR‐338‐3p /MTHFD1L and inactivation of the AKT/mTOR pathway
    Cheng‐Qun Wang et al, 2020, FEBS Open Bio CrossRef
  33. Autophagy in Osteosarcoma Cancer Stem Cells Is Critical Process which Can Be Targeted by the Antipsychotic Drug Thioridazine
    Olivier Camuzard et al, 2020, Cancers CrossRef
  34. Dis3L2 regulates cell proliferation and tissue growth though a conserved mechanism
    Benjamin P. Towler et al, 2020, PLoS Genet CrossRef
  35. Novel application of single-cell next-generation sequencing for determination of intratumoral heterogeneity of canine osteosarcoma cell lines
    Jordan Ayers et al, 2021, J VET Diagn Invest CrossRef
  36. Modulation of mTOR and epigenetic pathways as therapeutics in gallbladder cancer
    Dong Yang et al, 2021, Molecular Therapy - Oncolytics CrossRef
  37. Systematic Review of Recurrent Osteosarcoma Systemic Therapy.
    Ioanna Gazouli et al, 2021, Cancers (Basel) CrossRef
  38. Integrated bioinformatic analysis and experiment confirmation of the antagonistic effect and molecular mechanism of ginsenoside Rh2 in metastatic osteosarcoma
    Dan Liu et al, 2021, Journal of Pharmaceutical and Biomedical Analysis CrossRef
  39. Rhaponticin suppresses osteosarcoma through the inhibition of PI3K–Akt–mTOR pathway
    Suresh Mickymaray et al, 2021, Saudi Journal of Biological Sciences CrossRef
  40. Adjuvant Sirolimus Does Not Improve Outcome in Pet Dogs Receiving Standard-of-Care Therapy for Appendicular Osteosarcoma: A Prospective, Randomized Trial of 324 Dogs.
    Amy K LeBlanc et al, 2021, Clin Cancer Res CrossRef
  41. Genomic and Transcriptome Analysis to Identify the Role of the mTOR Pathway in Kidney Renal Clear Cell Carcinoma and Its Potential Therapeutic Significance
    Xiangyu Che et al, 2021, Oxidative Medicine and Cellular Longevity CrossRef
  42. Targeting the NAD Salvage Synthesis Pathway as a Novel Therapeutic Strategy for Osteosarcomas with Low NAPRT Expression
    Natasja Franceschini et al, 2021, IJMS CrossRef
  43. null
    Günther Richter et al, 2022 CrossRef
  44. AIM2 inhibits the proliferation, invasion and migration, and promotes the apoptosis of osteosarcoma cells by inactivating the PI3K/AKT/mTOR signaling pathway
    Jianping Zheng et al, 2021, Mol Med Rep CrossRef
  45. The anti-osteosarcoma cell activity by the sphingosine kinase 1 inhibitor SKI-V
    Xu Sun et al, 2022, Cell Death Discov. CrossRef
  46. Correlation of nuclear pIGF-1R/IGF-1R and YAP/TAZ in a tissue microarray with outcomes in osteosarcoma patients.
    Eric R Molina et al, 2022, Oncotarget CrossRef
  47. In Situ Analysis of mTORC1/C2 and Metabolism-Related Proteins in Pediatric Osteosarcoma
    Anna Mohás et al, 2022, Pathol. Oncol. Res. CrossRef
  48. Nitazoxanide inhibits osteosarcoma cells growth and metastasis by suppressing AKT/mTOR and Wnt/β-catenin signaling pathways
    Caihong Ye et al, 2022 CrossRef
  49. The roles of glycolysis in osteosarcoma
    Zuxi Feng et al, 2022, Front. Pharmacol. CrossRef
  50. ADCK1 is a potential therapeutic target of osteosarcoma
    Bao-biao Zhuo et al, 2022, Cell Death Dis CrossRef
  51. Drugging Hijacked Kinase Pathways in Pediatric Oncology: Opportunities and Current Scenario
    Marina Ferreira Candido et al, 2023, Pharmaceutics CrossRef
  52. Targeted therapy for osteosarcoma: a review
    Shizhe Li et al, 2023, J Cancer Res Clin Oncol CrossRef
  53. Translatome Regulation in Neuronal Injury and Axon Regrowth.
    Meir Rozenbaum et al, 2018, eNeuro CrossRef
  54. Prenylated PALM2 Promotes the Migration of Esophageal Squamous Cell Carcinoma Cells through Activating Ezrin
    Dan-Xia Deng et al, 2023, Molecular & Cellular Proteomics CrossRef
  55. HOXC13-driven TIMM13 overexpression promotes osteosarcoma cell growth
    Qicai Han et al, 2023, Cell Death Dis CrossRef
  56. Engineering a metastatic stroma directs the osteosarcoma tumour transcriptome in a spatially specific manner
    Deniz Bakkalci et al, 2023, Applied Materials Today CrossRef
  57. Reprogramming of glucose metabolism: Metabolic alterations in the progression of osteosarcoma
    Fangyu An et al, 2024, Journal of Bone Oncology CrossRef
  58. Targeting POLRMT by a first-in-class inhibitor IMT1 inhibits osteosarcoma cell growth in vitro and in vivo
    Yang Kong et al, 2024, Cell Death Dis CrossRef
  59. Unveiling the Protective Role of Melatonin in Osteosarcoma: Current Knowledge and Limitations
    Nojoud Al-Ansari et al, 2024, Biomolecules CrossRef
  60. mTORC1 accelerates osteosarcoma progression via m6A-dependent stabilization of USP7 mRNA
    Zhengming Yang et al, 2024, Cell Death Discov. CrossRef
  61. The Targeted Therapies for Osteosarcoma via Six Major Pathways
    Shuxing Wang et al, 2023, CMP CrossRef
  62. null
    Fardis Salmanpour et al, 2024 CrossRef
  63. Targeting the mitochondrial protein YME1L to inhibit osteosarcoma cell growth in vitro and in vivo
    Xu Sun et al, 2024, Cell Death Dis CrossRef
  64. Age-dependent molecular variations in osteosarcoma: implications for precision oncology across pediatric, adolescent, and adult patients
    Changye Zou et al, 2024, Front. Oncol. CrossRef